Subject: Bone and Tendon Graft Substitutes and Adjuncts
Reviewed: June 10, 2014
This Clinical Policy Bulletin explains how we determine whether certain services or supplies are medically necessary. We made these decisions based on a review of currently available clinical information including:
We expressly reserve the right to revise these conclusions as clinical information changes, and welcome further relevant information.
Each benefits plan defines which services are covered, excluded and subject to dollar caps or other limits. Members and their dentists will need to consult the member's benefits plan to determine if any exclusions or other benefits limitations apply to this service or supply. The conclusion that a particular service or supply is medically necessary does not guarantee that this service or supply is covered (that is, will be paid for by Aetna) for a particular member. The member's benefits plan determines coverage. Some plans exclude coverage for services or supplies that we consider medically necessary. If there is a discrepancy between this policy and a member's plan of benefits, the benefits plan will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the federal government or CMS for Medicare and Medicaid members.
D7921 -- Collection and application of autologous blood concentrate product
1 American Dental Association. Dental Procedure Codes, CDT 2014: 77.
Copyright 2013 American Dental Association. All rights reserved.
Original policy: July 12, 2012
Revised: August 12, 2013; June 10, 2014
Effective: September 17, 2014
See Medical Clinical Policy Bulletin 0411 -- Bone and Tendon Graft Substitutes and Adjuncts. Revised June 10, 2014: to state that hydroxyapatite bone substitute (for example, OtoMimix) is considered medically necessary for middle ear surgery. This CPB has been revised to state that the following are considered experimental and investigational: acellular human dermal allograft (for example, Alloderm and Arthrex allograft) for nasal septal repair, autologous stem cells for use after screw removal in orthopedic surgery, ceramic-based products (e.g., beta tri-calcium phosphate (b-TCP) when used alone or with bone marrow aspirate for the enhancement of bone healing and/or fusion, Cook anal fistula plug, Knee Creation nanocrystalline calcium phosphate bone substitute, nanOss Bioactive/nanOss Bioactive 3D in spinal surgeries, and OssiMend putty in spinal surgeries.
Property of Aetna. All rights reserved. Dental Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical/dental advice. This Dental Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating health care professionals are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating health care professionals are solely responsible for medical/dental advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.